CSIMarket
 


Odonate Therapeutics Inc   (ODT)
Other Ticker:  
 
 

ODT's Income from Cont. Operations Growth by Quarter and Year

Odonate Therapeutics Inc 's Income from Cont. Operations results by quarter and year




ODT Income from Cont. Operations (in millions $) FY 2021 FY 2020 FY 2019 FY 2018
IV Quarter December - -32.29 -84.09 -86.38
III Quarter September -14.00 -30.48 -26.63 -0.59
II Quarter June -22.02 -33.42 -0.61 -1.39
I Quarter March -33.77 -30.16 -0.50 -16.88
FY   -69.79 -126.35 -111.83 -105.24



ODT Income from Cont. Operations third quarter 2021 Y/Y Growth Comment
Odonate Therapeutics Inc in the third quarter 2021 recorded loss from continued operations of $ -14.00 millions.

According to the results reported in the third quarter 2021, Odonate Therapeutics Inc achieved the best Income from Cont. Operations growth in Major Pharmaceutical Preparations industry. While Odonate Therapeutics Inc ' s Income from Cont. Operations no change of % ranks overall at the positon no. in the third quarter 2021.




ODT Income from Cont. Operations ( Y/Y Growth %) 2021
2020 2019 2018
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Odonate Therapeutics Inc 's third quarter 2021 Income from Cont. Operations $ -14.00 millions ODT's Income Statement
Odonate Therapeutics Inc 's third quarter 2020 Income from Cont. Operations $ -30.48 millions Quarterly ODT's Income Statement
New: More ODT's historic Income from Cont. Operations Growth >>


ODT Income from Cont. Operations (Quarter on Quarter Growth %)

2021
2020 2019 2018
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Income from Cont. Operations third quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Income from Cont. Operations third quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Income from Cont. Operations by Quarter for the Fiscal Years 2018, 2019, 2020, 2021

Odonate Therapeutics Inc 's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ODT's III. Quarter Q/Q Income from Cont. Operations Comment
Although Odonate Therapeutics Inc in the III. Quarter 2021 revealed loss from continued operations of $ -14.00 millions, some analyst said, that this show improvement in contrast to the -22.02 millions in the second quarter.

Within Major Pharmaceutical Preparations industry Odonate Therapeutics Inc achieved highest sequential Income from Cont. Operations growth. While Odonate Therapeutics Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ODT's III. Quarter Q/Q Income from Cont. Operations Comment
Despite the fact, that Odonate Therapeutics Inc in the III. Quarter 2021 admitted loss from continued operations of $ -14.00 millions, it should be mentioned, that those numbers show improvement in contrast to the -22.02 millions in the second quarter.

Within Major Pharmaceutical Preparations industry Odonate Therapeutics Inc achieved highest sequential Income from Cont. Operations growth. While Odonate Therapeutics Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Odonate Therapeutics Inc 's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Sep 30 2021)
12 Months Ending
(Jun 30 2021)
12 Months Ending
(Mar 31 2021)
12 Months Ending
(Dec 31 2020)
12 Months Ending
(Sep 30 2020)
Cumulative Income from Cont. Operations 12 Months Ending $ -102.07 $ -118.55 $ -129.96 $ -126.35 $ -178.15
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) - - - - -
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # # # # #




Cumulative Income from Cont. Operations growth Comment


Odonate Therapeutics Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Income from Cont. Operations growth Comment


Odonate Therapeutics Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Income from Cont. Operations Growth
Major Pharmaceutical Preparations Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
ODT's Income from Cont. Operations Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for ODT's Competitors
Income from Cont. Operations Growth for Odonate Therapeutics Inc 's Suppliers
Income from Cont. Operations Growth for ODT's Customers

You may also want to know
ODT's Annual Growth Rates ODT's Profitability Ratios ODT's Asset Turnover Ratio ODT's Dividend Growth
ODT's Roe ODT's Valuation Ratios ODT's Financial Strength Ratios ODT's Dividend Payout Ratio
ODT's Roa ODT's Inventory Turnover Ratio ODT's Growth Rates ODT's Dividend Comparisons



Companies with similar Income from Cont. Operations no change for the quarter ending Sep 30 2021 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Sep 30 2021
Dexcom Inc -1.80%$ -1.801 millions
Select Medical Holdings Corp-4.06%$ -4.059 millions
Owens and Minor inc-4.24%$ -4.236 millions
United Therapeutics Corporation-4.96%$ -4.965 millions
Amgen Inc -6.78%$ -6.779 millions
Quidelortho Corp-7.11%$ -7.111 millions
Eli Lilly And Company-8.13%$ -8.135 millions
Abiomed Inc -8.45%$ -8.455 millions
Universal Health Services Inc -10.13%$ -10.126 millions
U S Physical Therapy Inc-10.40%$ -10.404 millions
Quest Diagnostics Inc-10.83%$ -10.829 millions
Lemaitre Vascular Inc -13.43%$ -13.430 millions
Vyne Therapeutics Inc -13.87%$ -13.875 millions
Semler Scientific Inc -14.71%$ -14.714 millions
Laboratory Corporation Of America Holdings-16.47%$ -16.470 millions
Bristol myers Squibb Company-17.36%$ -17.359 millions
Electromed Inc -17.98%$ -17.984 millions
Nature s Sunshine Products inc -23.87%$ -23.867 millions
Biostax Corp-23.97%$ -23.971 millions
Co diagnostics Inc -27.05%$ -27.051 millions
Elite Pharmaceuticals Inc -27.59%$ -27.587 millions
Collegium Pharmaceutical Inc -28.71%$ -28.708 millions
Biodelivery Sciences International Inc -28.92%$ -28.925 millions
Stryker Corp-29.47%$ -29.469 millions
Hologic Inc-33.29%$ -33.293 millions
Msa Safety Incorporated-33.33%$ -33.332 millions
Steris Plc-34.32%$ -34.321 millions
Viemed Healthcare Inc -36.20%$ -36.198 millions
Amedisys Inc -37.52%$ -37.516 millions
Organogenesis Holdings Inc -39.92%$ -39.921 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com